Allianz Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Allianz Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$516K	Buy	+4,500	New	+$387K	﹤0.01%	1985
2026 Q1	–	Sell	-5,500	Closed	-$428K	–	2070
2025 Q4	$428K	Buy	+5,500	New	+$371K	﹤0.01%	1853
2025 Q1	–	Sell	-9,600	Closed	-$386K	–	2295
2024 Q4	$386K	Buy	9,600 +1,000	+12%	+$45.2K	﹤0.01%	1935
2024 Q3	$407K	Buy	+8,600	New	+$380K	﹤0.01%	1907
2023 Q4	–	Sell	-13,200	Closed	-$183K	–	2194
2023 Q3	$183K	Hold	13,200	–	–	﹤0.01%	2128
2023 Q2	$303	Hold	13,200	–	–	﹤0.01%	2106
2023 Q1	$391K	Buy	+13,200	New	+$426K	﹤0.01%	1948
2022 Q3	–	Sell	-37,930	Closed	-$747K	–	2026
2022 Q2	$747K	Sell	37,930 -2,440	-6%	-$57K	﹤0.01%	1773
2022 Q1	$1.71M	Buy	+40,370	New	+$1.7M	﹤0.01%	1645

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Allianz Asset Management's KYMR Position: Q2 2026 in Review

Allianz Asset Management opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 4,500 shares worth $516K. The stake represents ﹤0.01% of the portfolio and ranks #1985 among its holdings. This is a return to the name: Allianz Asset Management previously reported a position in KYMR as recently as Q4 2025.

Allianz Asset Management first reported a position in KYMR in Q1 2022 and has held it in 9 quarters since. The position peaked at $1.71M in Q1 2022. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Allianz Asset Management held 4,500 shares of Kymera Therapeutics worth $516K as of Q2 2026.
Kymera Therapeutics was a new Allianz Asset Management position in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1985 holding.
Allianz Asset Management first reported a position in Kymera Therapeutics in Q1 2022 and has held it in 9 quarters since.
Allianz Asset Management's Kymera Therapeutics position peaked at $1.71M in Q1 2022.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.